Citi: Akeso (09926.HK) HARMONi-2 overall survival superiority reinforces ivonescimab's differentiated advantage; maintains "Buy" rating.

Citi released a research report stating that the interim readout of Akeso's (09926.HK) HARMONi-2 shows that ivonescimab, as a first-line monotherapy for PD-L1-positive non-small cell lung cancer, demonstrated meaningful overall survival superiority compared with pembrolizumab, reinforcing its differentiated positioning, while global readouts remain key. The bank maintained its "Buy" rating on Akeso with an unchanged target price of HK$171.